Since the merger of Glaxo Wellcome and SmithKline Beecham in 2001, she presided over record country performances during a turbulent period of regulation in Taiwan's pharmaceutical industry. During her tenure as Managing Director of SmithKline Beecham Taiwan, she oversaw the launches of novel products, such as Engerix B, Tagamet, Augmentin, Avandia, and Seretide, representing some of the most successful.
Cheng-Der (Tony) Yu
Chief Science Officer & Executive Vice President
Chief Financial Officer
Executive Vice President, R&D
Vice President of Medical Affairs and Clinical Development
Prior to joining OBI Pharma, Dr. Tsai was Vice President of Clinical Development successively at TWi Biotechnology and TaiGen Biotechnology. He supervised the design, initiation, execution, and data analysis of clinical studies, from Phase 1 to Phase 4, and was responsible for all medical affairs activities. At TaiGen, he led the team to finish the pivotal Phase 3 study of a new drug, and to gain its marketing approval in Taiwan and China. Dr. Tsai also was a Senior Principal Researcher for 5 years at the Divisions of Clinical Sciences and HTA of Taiwan's Center for Drug Evaluation. His therapeutic area expertise includes breast cancer, leukemia, diabetes, gout, osteoarthritis, infectious diseases, and rare diseases.
Vice President of Quality Assurance & Supply Chain
Vice President of Statistic & Biometrics
Vice President of Research
Chief Operating Officer (USA)
Kevin P Poulos
Chief Commerical Officer (USA)
Global RA VP (USA)